In addition to BRCA1/2, the newly recommended standard therapies include an immune checkpoint inhibitor for MSI‐H, trastuzumab regimen for ERBB2 amplification, BRAF/MEK inhibitor for BRAF V600E, tyrosine kinase inhibitors for the fusion of NTRK1,3, RET, and ROS1, and everolimus for PTEN mutations or deletions in breast cancer. This evidence concerns the gene RET and breast carcinoma.